Market Runner: Anthera Pharmaceuticals Inc Stock Is Crashing Now

Market Runner: Anthera Pharmaceuticals Inc Stock Is Crashing Now

The stock of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) is a huge mover today! About 377,122 shares traded hands. Anthera Pharmaceuticals Inc (NASDAQ:ANTH) has declined 32.83% since March 9, 2016 and is downtrending. It has underperformed by 40.25% the S&P500.
The move comes after 8 months negative chart setup for the $122.40M company. It was reported on Oct, 12 by Barchart.com. We have $2.64 PT which if reached, will make NASDAQ:ANTH worth $15.91M less.

Analysts await Anthera Pharmaceuticals Inc (NASDAQ:ANTH) to report earnings on November, 4. They expect $-0.35 earnings per share, down 20.69% or $0.06 from last year’s $-0.29 per share. After $-0.35 actual earnings per share reported by Anthera Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Ratings Coverage

Out of 4 analysts covering Anthera Pharmaceuticals (NASDAQ:ANTH), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Anthera Pharmaceuticals has been the topic of 7 analyst reports since August 13, 2015 according to StockzIntelligence Inc. H.C. Wainwright initiated the stock with “Buy” rating in Friday, July 8 report. Suntrust Robinson initiated the stock with “Buy” rating in Wednesday, September 9 report. The firm earned “Buy” rating on Wednesday, September 9 by SunTrust. As per Friday, February 19, the company rating was reinitiated by Jefferies. The firm has “Buy” rating by Citigroup given on Thursday, September 17. The stock has “Hold” rating given by Zacks on Thursday, August 13.

According to Zacks Investment Research, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California.”

Insitutional Activity: The institutional sentiment increased to 1.7 in Q2 2016. Its up 0.76, from 0.94 in 2016Q1. The ratio improved, as 6 funds sold all Anthera Pharmaceuticals Inc shares owned while 14 reduced positions. 5 funds bought stakes while 29 increased positions. They now own 22.69 million shares or 1.80% less from 23.11 million shares in 2016Q1.
Blackrock Investment Ltd Liability holds 0% of its portfolio in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) for 152,291 shares. Commonwealth Equity Services owns 10,895 shares or 0% of their US portfolio. Moreover, Bank & Trust Of New York Mellon has 0% invested in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) for 230,767 shares. Abingworth Llp accumulated 1.41% or 437,994 shares. Jpmorgan Chase & has 0% invested in the company for 2,126 shares. Legal & General Gru Public Ltd Liability Co owns 5,480 shares or 0% of their US portfolio. Goldman Sachs Grp, a New York-based fund reported 19,582 shares. Moreover, New York State Common Retirement Fund has 0% invested in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) for 38,000 shares. Voya Mgmt Ltd last reported 19,647 shares in the company. Moreover, Smith Asset Mgmt Group Inc Inc L P has 0% invested in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) for 49,120 shares. Manufacturers Life Ins Com The holds 0% or 1,579 shares in its portfolio. Vanguard Grp reported 1.48M shares or 0% of all its holdings. Weiss Multi has 0.01% invested in the company for 60,143 shares. Northern Corporation last reported 0% of its portfolio in the stock. Credit Suisse Ag holds 0% or 23,397 shares in its portfolio.

More notable recent Anthera Pharmaceuticals Inc (NASDAQ:ANTH) news were published by: Fool.com which released: “Why Anthera Pharmaceuticals, Inc. Shares Are Soaring Higher” on June 05, 2015, also Marketwatch.com with their article: “Anthera Pharma stock rises 7% on safety review board’s go-ahead for late-stage …” published on August 16, 2016, Seekingalpha.com published: “Anthera Pharmaceuticals: Buy Low Opportunity On Potential Drug Approval” on February 02, 2016. More interesting news about Anthera Pharmaceuticals Inc (NASDAQ:ANTH) were released by: Thestreet.com and their article: “Anthera Pharmaceuticals (ANTH) Stock Dropping After Pricing Public Offering” published on July 09, 2015 as well as 247Wallst.com‘s news article titled: “Tuesday’s Top Health Care Movers” with publication date: August 16, 2016.

ANTH Company Profile

Anthera Pharmaceuticals, Inc. (Anthera), incorporated on October 9, 2004, is a biopharmaceutical firm focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment